Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 450
- 试验地点
- 1
- 主要终点
- Summary of Schizophrenia
研究概览
简要总结
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
详细描述
Sampling Method Details: Non-interventional study (subjects chosen by physician in accordance to their usual practice).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Usual clinical practice of physician
排除标准
- 未提供
结局指标
主要结局
Summary of Schizophrenia
时间窗: Baseline
Stage, symptoms and type of schizophrenia were recorded in addition to demographic and other clinical history data at the Baseline visit. The primary outcome was to assess the participants profile. Some assessments have been included in the Baseline demographics. This outcome presents results for the Summary of Schizophrenia.
Summary of Metabolic Risk Factors
时间窗: Baseline
Summary of Most Frequently Used Concomitant Drug Treatments
时间窗: Baseline
Most frequently concomitant drug treatments used by \>15 participants.
次要结局
- Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)(Week 12)
- Number of Participants With Categorical Scores on Clinical Global Impression of Severity (CGI-S)(Baseline, Week 12)
- Positive and Negative Syndrome Scale (PANSS) - Positive Subscale(Baseline, Week 12)
- Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Physical Health and Ability to Function (ie, Ability to Think Clearly, Stay Awake, Etc)?"(Week 12)
- Number of Participants Answering the Question "To What Extent do the Side Effects Interfere With Your Mental Function (ie, Ability to Think, Stay Awake, Etc)?"(Week 12)
- Number of Participants Answering the Question "To What Degree Have Medication Side Effects Affected Your Overall Satisfaction With the Medication?"(Week 12)
- Number of Participants Answering the Question "How Easy or Difficult is it to Use the Medication in Its Current Form?"(Week 12)
- Number of Participants Answering the Question "How Easy or Difficult is it to Plan When You Will Use the Medication Each Time?"(Week 12)
- Number of Participants Answering the Question "How Convenient or Inconvenient is it to Take the Medication as Instructed?"(Week 12)
- Percent Change From Baseline to Final Visit in Body Weight(Baseline, Week 12)
- Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Way the Medication Relieves Your Symptoms?"(Week 12)
- PANSS - Negative Subscale(Baseline, Week 12)
- PANSS - Composite Subscale(Baseline, Week 12)
- Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Ability of the Medication to Prevent or Treat Your Condition?"(Week 12)
- Number of Participants Answering the Question "How Satisfied or Dissatisfied Are You With the Amount of Time it Takes the Medication to Start Working?"(Week 12)
- Number of Participants Answering the Question "As a Result of Taking This Medication, do You Experience Any Side Effects at All?"(Week 12)
- Number of Participants Answering the Question "How Bothersome Are the Side Effects of the Medication You Take to Treat Your Condition?"(Week 12)
- Number of Participants Answering the Question "Overall, How Confident Are You That Taking This Medication is a Good Thing?"(Week 12)
- Number of Participants Answering the Question "How Certain Are You That the Good Things About Your Medication Outweigh the Bad Things?"(Week 12)
- Number of Participants Answering the Question "Taking All Things Into Account, How Satisfied or Dissatisfied Are You With This Medication?"(Week 12)
